850991-69-4

Basic information

• Product Name: 5-Methoxypyridine-3-boronic acid
• Synonyms: 5-METHOXYPYRIDINE-3-BORONIC ACID;5-METHOXY-3-PYRIDINYLBORONIC ACID;3-methoxy-5-pyridineboronic aci98%;5-methoxy-3-pyridineboronic acid;5-Methoxypyridin-3-ylboronic acid;3-methoxy-5-pyridineboronic acid;5-Methoxypyridine-3-boronic acid ,98%;5-Methoxypyridin-3-yl-3-boronic acid
• CAS NO: 850991-69-4
• Molecular Formula: C₆H₈BNO₃
• Molecular Weight: 152.94
• EINECS: 1592732-453-0
• Product Categories: blocks;BoronicAcids;Pyridines;Organoborons;Pyridine;Boronic acid
• Mol File: 850991-69-4.mol

Chemical Properties

• Boiling Point: 356.2 °C at 760 mmHg
• Flash Point: 169.2 °C
• Appearance: White to off-white/Powder
• Density: 1.24 g/cm³
• Vapor Pressure: 1.08E-05mmHg at 25°C
• Refractive Index: 1.523
• PKA: 3.58±0.10(Predicted)
• CAS DataBase Reference: 5-Methoxypyridine-3-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methoxypyridine-3-boronic acid(850991-69-4)
• EPA Substance Registry System: 5-Methoxypyridine-3-boronic acid(850991-69-4)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 26-39
• Hazardous Substances Data: 850991-69-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Methoxypyridine-3-boronic acid is utilized as a key building block in the synthesis of various pharmaceuticals and agrochemicals. Its capacity to engage in cross-coupling reactions with organic halides makes it a valuable reagent for constructing complex organic molecules, which are essential in the development of new drugs and chemical products.
Used in the Development of New Materials:
Due to its distinctive structural and chemical properties, 5-Methoxypyridine-3-boronic acid is employed in the research and development of innovative materials. Its integration into material science can lead to advancements in areas such as polymers, coatings, and other specialty materials that require specific chemical functionalities.
Used in Pharmaceutical Intermediates:
5-Methoxypyridine-3-boronic acid serves as a crucial intermediate in the pharmaceutical industry. Its presence in the synthesis process allows for the creation of intermediate compounds that are precursors to final drug products, thereby playing a significant role in the production of various medications.

InChI:InChI=1/C6H8BNO3/c1-11-6-2-5(7(9)10)3-8-4-6/h2-4,9-10H,1H3

Upstream product

• 50720-12-2 3-bromo-5-methoxypyridine 

Downstream Products

• 1219095-73-4 5-(2-fluorophenyl)-4-(5-methoxy-3-pyridinyl)-3-(2,4,6-trifluorophenyl)-2(5H)-furanone 
• 1354288-22-4 6-chloro-5'-methoxy-3,3'-bipyridin-4-amine 
• 1369542-77-7 rac-4-[3-(5-methoxypyridin-3-yl)-phenyl]-4-methyl-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrazin-6-amine 
• 1369543-24-7 rac-4-[3-(5-methoxypyridin-3-yl)phenyl]-4-methyl-4,5-dihydropyrazolo[1,5-a]pyrazine-6-thione 
• 1214909-15-5 C₂₄H₂₃F₂N₅O₂ 
• 1425041-71-9 (S)-2-amino-4-((1-(8-(5-methoxypyridin-3-yl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)amino)pyrimidine-5-carbonitrile 
• 1425041-72-0 2-amino-4-((S)-1-(8-(5-methoxypyridin-3-yl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethylamino)pyrimidine-5-carboxamide 
• 29681-46-7 methyl 5-methoxypyridine-3-carboxylate 
• 1260536-29-5 2-((trans-4-hydroxycyclohexyl)amino)-4-(3-isopropyl-4-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzonitrile 
• 1219095-74-5 5-(2-fluorophenyl)-5-hydroxy-4-(5-methoxy-3-pyridinyl)-3-(2,4,6-trifluorophenyl)-2(5H)-furanone 
• 1219095-58-5 3-chloro-6-(2-fluorophenyl)-5-(5-methoxy-3-pyridinyl)-4-(2,4,6-trifluorophenyl)pyridazine 
• 1219095-75-6 6-(2-fluorophenyl)-5-(5-methoxy-3-pyridinyl)-4-(2,4,6-trifluorophenyl)-3(2H)-pyridazone 

Relevant articles and documents

2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING Aβ-RELATED PATHOLOGIES

This invention relates to novel compounds having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds prov

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas (1 or 2), as described herein. The compounds of Formulas (1 and 2) are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.